Research location
Cona
FE, Italy
Advertisement
Research activity in Cona
FE, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 30 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cona
30 linked trials · page 1 of 1A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCNCT07226986 · 2025-12-05 · 1 site observation
RECRUITING
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate CancerNCT07093801 · 2025-07-30 · 1 site observation
RECRUITING
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.NCT05939414 · 2024-03-12 · 1 site observation
RECRUITING
PREgnancy and FERtility RegistryNCT02895165 · 2012-11-01 · 1 site observation
RECRUITING
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung CancerNCT07418931 · 2026-05-01 · 1 site observation
NOT_YET_RECRUITING
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsNCT06345157 · 2024-07-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantNCT03439046 · 2018-02-02 · 1 site observation
TERMINATED
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsNCT04659551 · 2017-10-05 · 1 site observation
COMPLETED
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MINCT02924727 · 2016-12-09 · 1 site observation
COMPLETED
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCNCT02941926 · 2016-11-30 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection FractionNCT02884206 · 2016-11-23 · 1 site observation
COMPLETED
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabNCT02926196 · 2016-06-17 · 1 site observation
COMPLETED
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02563067 · 2015-12-03 · 1 site observation
COMPLETED
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerNCT02278120 · 2014-11-20 · 1 site observation
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16 · 1 site observation
COMPLETED
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer PatientsNCT02511639 · 2014-07-30 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection FractionNCT01920711 · 2014-07-18 · 1 site observation
COMPLETED
Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal TherapyNCT02411344 · 2014-02-01 · 1 site observation
COMPLETED
Safety and Tolerability of Initiating LCZ696 in Heart Failure PatientsNCT01922089 · 2013-11-01 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHFNCT01870778 · 2013-10-02 · 1 site observation
COMPLETED
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast CancerNCT02918084 · 2013-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiNCT01633060 · 2012-10-03 · 1 site observation
TERMINATED
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationNCT01572727 · 2012-08-01 · 1 site observation
COMPLETED
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)NCT01555138 · 2012-02-01 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailureNCT01035255 · 2009-12-01 · 1 site observation
TERMINATED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Exacerbation StudyNCT00845728 · 2009-03-01 · 1 site observation
COMPLETED
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)NCT00549757 · 2007-10-01 · 1 site observation
TERMINATED
Efficacy and Safety of LCZ696A in Patients With Essential HypertensionNCT00549770 · 2007-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.